You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
VU 6028418 hydrochloride New
Biological Activity for VU 6028418 hydrochloride
VU 6028418 hydrochloride is a potent and selective M4 mAChR antagonist (IC50 = 4.1 nM and 57 nM for human and rat M4 respectively). VU 6028418 hydrochloride dose-dependently reduces the latency to withdraw and reverses cataleptic behavior in haloperidol-treated animals. Orally bioavailable.
Sold under license from Vanderbilt University
Technical Data for VU 6028418 hydrochloride
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for VU 6028418 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for VU 6028418 hydrochloride
The following data is based on the product molecular weight 468.95. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.13 mL||10.66 mL||21.32 mL|
|5 mM||0.43 mL||2.13 mL||4.26 mL|
|10 mM||0.21 mL||1.07 mL||2.13 mL|
|50 mM||0.04 mL||0.21 mL||0.43 mL|
Product Datasheets for VU 6028418 hydrochloride
References for VU 6028418 hydrochloride
References are publications that support the biological activity of the product.
Spock et al (2021) Discovery of VU6028418: a highly selective and orally bioavailable M4 muscarinic acetylcholine receptor antagonist. ACS Med.Chem.Lett. 12 1342 PMID: 34413964
If you know of a relevant reference for VU 6028418 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: VU 6028418 hydrochloride, VU 6028418 hydrochloride supplier, VU6028418, hydrochloride, potent, selective, Acetylcholine, Receptor, Cholinergic, Muscarinic, 4, antagonist, dystonia, mAChR, ACh, M4, Receptors, 7658, Tocris Bioscience
Citations for VU 6028418 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for VU 6028418 hydrochloride. Do you know of a great paper that uses VU 6028418 hydrochloride from Tocris? Please let us know.
Reviews for VU 6028418 hydrochloride
There are currently no reviews for this product. Be the first to review VU 6028418 hydrochloride and earn rewards!
Have you used VU 6028418 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.